FONT-SIZE Plus   Neg

Boehringer Ingelheim, Lilly's Jentadueto Now Available In U.S. Pharmacies

Eli Lilly and Co. (LLY) and Boehringer Ingelheim Pharmaceuticals, Inc. said Jentadueto tablets are now available by prescription in many leading chain and independent pharmacies across the U.S.

JENTADUETO is a new prescription medication for patients who need to control their blood sugar. Taken twice daily, it combines two diabetes medicines, the dipeptidyl peptidase-4 inhibitor, linagliptin, and metformin, in one tablet.

JENTADUETO provides physicians with options to adjust the metformin dosing based on effectiveness and tolerability. It is available in three dosage strengths, taken twice daily: 2.5 mg linagliptin/500 mg metformin hydrochloride; 2.5 mg linagliptin/850 mg metformin hydrochloride; and 2.5 mg linagliptin/1000 mg metformin hydrochloride.

"By combining two important diabetes medicines in a single tablet, JENTADUETO provides people with type 2 diabetes another option to control their blood sugar," said David Pass, PharmD, vice president, cardiovascular and metabolic disorders marketing, Boehringer Ingelheim Pharmaceuticals, Inc.

"Making JENTADUETO available quickly following its approval further demonstrates Boehringer Ingelheim and Lilly's shared commitment to address the needs of the millions of Americans living with type 2 diabetes."

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
The U.S. Consumer Products Safety Commission has asked Safety 1st to recall 35,000 highchairs after several children fell and were injured. The recall covers about 35,000 wooden Safety 1st highchairs in three models: HC144BZF (Casablanca), HC229CZF (Gentle Lace) and HC229CYG (Black Lace). Safety... Ferrari, the luxury car division of Fiat Chrysler Automobiles (FCAU) is reportedly getting a much higher valuation than previously expected driven by its premium status of manufacturing high-performance luxury cars. According to reports, Ferrari expects the IPO to bring its market valuation to about... SeaWorld Entertainment Inc. (SEAS) has received another blow to its business as the California Coastal Commission banned breeding of captive killer whales in San Diego. The new law means SeaWorld won't be allowed to breed captive orcas, including through artificial insemination, at its California...
comments powered by Disqus
Follow RTT